US20070117153A1 - Molecular conjugate - Google Patents

Molecular conjugate Download PDF

Info

Publication number
US20070117153A1
US20070117153A1 US11/603,425 US60342506A US2007117153A1 US 20070117153 A1 US20070117153 A1 US 20070117153A1 US 60342506 A US60342506 A US 60342506A US 2007117153 A1 US2007117153 A1 US 2007117153A1
Authority
US
United States
Prior art keywords
conjugate
hydrazide
linker
molecule
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/603,425
Other languages
English (en)
Inventor
Christopher Bieniarz
Julia Ashworth-Sharpe
Casey Kernag
Jerome Kosmeder
Mark Lefever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventana Medical Systems Inc
Original Assignee
Christopher Bieniarz
Julia Ashworth-Sharpe
Kernag Casey A
Kosmeder Jerome W
Mark Lefever
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christopher Bieniarz, Julia Ashworth-Sharpe, Kernag Casey A, Kosmeder Jerome W, Mark Lefever filed Critical Christopher Bieniarz
Priority to US11/603,425 priority Critical patent/US20070117153A1/en
Publication of US20070117153A1 publication Critical patent/US20070117153A1/en
Assigned to VENTANA MEDICAL SYSTEMS, INC. reassignment VENTANA MEDICAL SYSTEMS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASHWORTH-SHARPE, JULIA, LEFEVER, MARK, KERNAG, CASEY A., BIENIARZ, CHRISTOPHER, KOSMEDER, JEROME W.
Priority to US12/687,564 priority patent/US8686122B2/en
Priority to US14/181,391 priority patent/US9310373B2/en
Priority to US15/052,768 priority patent/US20160195540A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/02—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/28—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
US11/603,425 2005-11-23 2006-11-21 Molecular conjugate Abandoned US20070117153A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/603,425 US20070117153A1 (en) 2005-11-23 2006-11-21 Molecular conjugate
US12/687,564 US8686122B2 (en) 2005-11-23 2010-01-14 Molecular conjugate
US14/181,391 US9310373B2 (en) 2005-11-23 2014-02-14 Molecular conjugate
US15/052,768 US20160195540A1 (en) 2005-11-23 2016-02-24 Molecular Conjugate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73979405P 2005-11-23 2005-11-23
US11/603,425 US20070117153A1 (en) 2005-11-23 2006-11-21 Molecular conjugate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/687,564 Continuation US8686122B2 (en) 2005-11-23 2010-01-14 Molecular conjugate

Publications (1)

Publication Number Publication Date
US20070117153A1 true US20070117153A1 (en) 2007-05-24

Family

ID=37793952

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/603,425 Abandoned US20070117153A1 (en) 2005-11-23 2006-11-21 Molecular conjugate
US12/687,564 Active 2029-01-18 US8686122B2 (en) 2005-11-23 2010-01-14 Molecular conjugate
US14/181,391 Active 2026-12-13 US9310373B2 (en) 2005-11-23 2014-02-14 Molecular conjugate
US15/052,768 Abandoned US20160195540A1 (en) 2005-11-23 2016-02-24 Molecular Conjugate

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/687,564 Active 2029-01-18 US8686122B2 (en) 2005-11-23 2010-01-14 Molecular conjugate
US14/181,391 Active 2026-12-13 US9310373B2 (en) 2005-11-23 2014-02-14 Molecular conjugate
US15/052,768 Abandoned US20160195540A1 (en) 2005-11-23 2016-02-24 Molecular Conjugate

Country Status (10)

Country Link
US (4) US20070117153A1 (US20070117153A1-20070524-C00013.png)
EP (3) EP2963011B1 (US20070117153A1-20070524-C00013.png)
JP (1) JP5199880B2 (US20070117153A1-20070524-C00013.png)
CN (2) CN101535244B (US20070117153A1-20070524-C00013.png)
AU (1) AU2006318438B2 (US20070117153A1-20070524-C00013.png)
CA (1) CA2631005C (US20070117153A1-20070524-C00013.png)
DK (2) DK1951316T3 (US20070117153A1-20070524-C00013.png)
ES (3) ES2804129T3 (US20070117153A1-20070524-C00013.png)
HK (2) HK1121054A1 (US20070117153A1-20070524-C00013.png)
WO (1) WO2007062177A2 (US20070117153A1-20070524-C00013.png)

Cited By (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246523A1 (en) * 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
US20060246524A1 (en) * 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates
US20080268462A1 (en) * 2006-11-01 2008-10-30 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US20080274463A1 (en) * 2007-05-04 2008-11-06 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
WO2009055387A1 (en) * 2007-10-22 2009-04-30 Thermo Fisher Scientific Polymerized conjugates for biological applications
US20100136652A1 (en) * 2005-11-23 2010-06-03 Christopher Bieniarz Molecular Conjugate
WO2010078376A2 (en) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
US20100324008A1 (en) * 2007-08-17 2010-12-23 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2011082293A1 (en) 2009-12-31 2011-07-07 Ventana Medical Systems, Inc. Methods for producing uniquely specific nucleic acid probes
US20110203023P1 (en) * 2010-02-16 2011-08-18 Menachem Bronstein Gypsophila Plant Named 'Pearl Blossom''
WO2012003478A2 (en) 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry
WO2012003476A2 (en) 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Hapten conjugates for target detection
WO2012116949A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Application of quantum dots for nuclear staining
US8445191B2 (en) 2007-05-23 2013-05-21 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US20130295641A1 (en) * 2005-12-12 2013-11-07 Innova Biosciences, Ltd. Production of Conjugates
WO2013167387A1 (en) 2012-05-10 2013-11-14 Ventana Medical Systems, Inc. Uniquely specific probes for pten, pik3ca, met, top2a, and mdm2
WO2014009535A2 (en) 2012-07-12 2014-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
WO2014023706A1 (en) 2012-08-06 2014-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for screening patients with a cancer
WO2014048942A1 (en) 2012-09-25 2014-04-03 Ventana Medical Systems, Inc. Probes for pten, pik3ca, met, and top2a, and method for using the probes
US8703490B2 (en) 2008-06-05 2014-04-22 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
WO2015001082A1 (en) 2013-07-05 2015-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
WO2015036405A1 (en) 2013-09-10 2015-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating basal cell carcinoma
US9127028B2 (en) 2010-08-16 2015-09-08 Ventana Medical Systems, Inc. Substrates for chromogenic detection and methods of use in detection assays and kits
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
US9636413B2 (en) 2012-11-15 2017-05-02 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
WO2017202962A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2018011107A1 (en) 2016-07-11 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of er-alpha 46 in methods and kits for assessing the status of breast cancer
WO2018046736A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018055080A1 (en) 2016-09-22 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
WO2018055023A1 (en) 2016-09-22 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of lung cancer
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2018146239A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker for outcome in aml patients
WO2018162404A1 (en) 2017-03-06 2018-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker for outcome in aml patients
WO2018172540A1 (en) 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to predict the progression of alzheimer's disease
WO2018189215A1 (en) 2017-04-12 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from hepatocellular carcinoma
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2019038219A1 (en) 2017-08-21 2019-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) NEW PROGNOSTIC METHOD OF PANCREATIC CANCER
WO2019043138A1 (en) 2017-09-01 2019-03-07 INSERM (Institut National de la Santé et de la Recherche Médicale) METHOD FOR PREDICTING OUTCOME OF CANCER
WO2019092269A1 (en) 2017-11-13 2019-05-16 F. Hoffmann-La Roche Ag Devices for sample analysis using epitachophoresis
US10398791B2 (en) 2013-10-18 2019-09-03 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2020074742A1 (en) 2018-10-12 2020-04-16 F. Hoffmann-La Roche Ag Detection methods for epitachophoresis workflow automation
WO2020089428A1 (en) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
WO2020089432A1 (en) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
WO2020141199A1 (en) 2019-01-03 2020-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
WO2020148349A1 (en) 2019-01-16 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Variants of erythroferrone and their use
WO2020165370A1 (en) 2019-02-13 2020-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020182932A1 (en) 2019-03-13 2020-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) New gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2020193740A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020216832A1 (en) 2019-04-24 2020-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the response of antipsychotic drugs
WO2020229437A1 (en) 2019-05-14 2020-11-19 F. Hoffmann-La Roche Ag Devices and methods for sample analysis
WO2020229521A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for inhibiting or reducing bacterial biofilms on a surface
WO2020245155A1 (en) 2019-06-03 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating a treatment regimen
WO2021001539A1 (en) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to detect and treat eosinophilic fasciitis
WO2021044012A1 (en) 2019-09-05 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment and pronostic of acute myeloid leukemia
WO2021074391A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing nasal intestinal type adenocarcinomas
WO2021170777A1 (en) 2020-02-28 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
WO2021186014A1 (en) 2020-03-20 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from a cancer
WO2021250106A1 (en) 2020-06-10 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and prognosing cancer like glioblastoma
WO2021255204A1 (en) 2020-06-18 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2022002873A1 (en) 2020-06-30 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
WO2022002874A1 (en) 2020-06-30 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
WO2022018163A1 (en) 2020-07-22 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting survival time in patients suffering from cancer
WO2022064049A1 (en) 2020-09-28 2022-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing brucella infection
WO2022084327A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the response to tnf inhibitors
WO2022096633A1 (en) 2020-11-06 2022-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treating polycystic ovary syndrome (pcos)
WO2022136252A1 (en) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for prognosis the humoral response of a subject prior to vaccination
WO2022135753A1 (en) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for prognosis the humoral response of a subject prior to vaccination
WO2022152698A1 (en) 2021-01-12 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of npdk-d to evaluate cancer prognosis
WO2022171611A1 (en) 2021-02-09 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to pronostic lung cancer
WO2022194949A1 (en) 2021-03-17 2022-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing pancreatic cancer
WO2022207566A1 (en) 2021-03-29 2022-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to evaluate pancreatic cancer prognosis
WO2022223791A1 (en) 2021-04-23 2022-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cell senescence accumulation related disease
WO2023280790A1 (en) 2021-07-05 2023-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2023089159A1 (en) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy targeting stroma/tumor cell crosstalk to treat a cancer
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011000861A (es) * 2008-07-23 2011-06-21 Hanmi Holdings Co Ltd Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales.
CA2788664C (en) 2010-03-04 2023-04-11 Ventana Medical Systems, Inc. Processing system for processing specimens using acoustic energy
US10126216B2 (en) 2011-02-17 2018-11-13 Ventana Medical Systems, Inc. Method for tissue sample fixation
US10539487B2 (en) 2010-03-04 2020-01-21 Ventana Medical Systems, Inc. Systems and methods for monitoring tissue sample processing
CN103384681B (zh) 2010-12-23 2018-05-18 霍夫曼-拉罗奇有限公司 结合剂
EP2659269B1 (en) * 2010-12-23 2016-10-26 Roche Diagniostics GmbH Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
CN103534359B (zh) 2011-03-14 2016-07-06 文塔纳医疗系统公司 分析染色体易位的方法及其系统
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
CN103901191A (zh) * 2012-12-25 2014-07-02 深圳先进技术研究院 纳米金靶向标记抗体的造影剂及其制备方法
CN103901187A (zh) * 2012-12-25 2014-07-02 深圳先进技术研究院 纳米金靶向标记抗体复合物及其制备方法
EP2971064B1 (en) 2013-03-12 2019-10-16 Ventana Medical Systems, Inc. Proximity assay for in situ detection of targets
CA2912664C (en) * 2013-05-20 2022-07-26 Yale University Anti-thrombogenic grafts
CN103439493A (zh) * 2013-08-08 2013-12-11 南京大渊生物技术工程有限责任公司 适配子渗滤式生物芯片及制备方法
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
RU2744836C2 (ru) 2014-05-08 2021-03-16 Новодиакс, Инк. Прямой иммуногистохимический анализ
US10018635B2 (en) 2014-07-30 2018-07-10 Novilytic, LLC Method for analyzing samples of a biological fluid
EP3224621B1 (en) 2014-11-25 2019-06-12 Ventana Medical Systems, Inc. Proximity assays using chemical ligation and hapten transfer
JP6908531B2 (ja) 2015-01-27 2021-07-28 ベンタナ メディカル システムズ， インコーポレイテッド アルデヒドに基づく固定溶液における長時間浸漬を用いる、組織試料固定法
WO2016146616A1 (en) 2015-03-16 2016-09-22 Ventana Medical Systems, Inc. Control slides for immunohistochemistry generated from three-dimensional cell line cultures
CN107923915B (zh) 2015-08-28 2021-05-04 文塔纳医疗系统公司 使用经掩蔽的半抗原在福尔马林固定石蜡包埋的组织中的蛋白质邻近测定
WO2017155996A1 (en) 2016-03-08 2017-09-14 Ventana Medical Systems, Inc. Multiplexed immunohistochemistry using recombinant antibodies with epitope tags
WO2018002015A1 (en) 2016-06-28 2018-01-04 Ventana Medical Systems, Inc. New colors for chromogenic ihc and ish staining with multi-dye quinone methide and tyramide conjugates
JP7128121B2 (ja) 2016-06-28 2022-08-30 ヴェンタナ メディカル システムズ， インク． Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
CN109205774A (zh) * 2018-10-19 2019-01-15 佛山科学技术学院 一种基于a2o2创新工艺的mbr膜生物反应器
JP2022533577A (ja) 2019-05-14 2022-07-25 ヴェンタナ メディカル システムズ， インク． 生物学的試料処理チャンバを含むシステム
WO2022152777A1 (en) 2021-01-15 2022-07-21 F. Hoffmann-La Roche Ag Storage stable caged haptens
CN116868054A (zh) 2021-01-25 2023-10-10 文塔纳医疗系统公司 包括用一个或多个可检测部分标记的一种或多种生物标志物的染色生物学样本

Citations (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3839153A (en) * 1970-12-28 1974-10-01 Akzona Inc Process for the detection and determination of specific binding proteins and their corresponding bindable substances
US4002532A (en) * 1974-10-21 1977-01-11 Weltman Joel K Enzyme conjugates
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4101380A (en) * 1975-06-12 1978-07-18 Research Products Rehovot Ltd. Process for the cross-linking of proteins
US4182695A (en) * 1977-02-24 1980-01-08 Boehringer Mannheim Gmbh Polyamide-fixed biologically active protein
US4200436A (en) * 1976-09-30 1980-04-29 Mochida Seiyaku Kabushiki Kaisha Immunochemical measuring process
US4218539A (en) * 1978-03-24 1980-08-19 Weltman Joel K Enzyme conjugates and method of preparation and use
US4232119A (en) * 1977-03-04 1980-11-04 Pharmacia Diagnostics Ab Reagent for use in immunochemical assay methods
US4235960A (en) * 1977-07-29 1980-11-25 The Medical College Of Wisconsin, Inc. Competitive enzyme-linked immunoassay
US4433059A (en) * 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4454226A (en) * 1982-03-17 1984-06-12 Majid Ali Enzymatic immunoassay
US4657853A (en) * 1984-09-14 1987-04-14 E. I. Du Pont De Nemours And Company Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4994385A (en) * 1987-10-30 1991-02-19 Abbott Laboratories Heterobifunctional coupling agents
US5002883A (en) * 1987-10-30 1991-03-26 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
US5053520A (en) * 1988-09-22 1991-10-01 Abbott Laboratories Heterobifunctional maleimido containing coupling agents
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5063109A (en) * 1988-10-11 1991-11-05 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
US5191066A (en) * 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
US5648218A (en) * 1993-02-12 1997-07-15 Sealite Sciences, Inc. Preparation of photoprotein conjugates and methods of use thereof
US5759808A (en) * 1992-08-21 1998-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5789219A (en) * 1994-12-02 1998-08-04 Abbott Laboratories Phosphatase activated crosslinking conjugating and reducing agents; methods of using such agents; and reagents comprising phosphatase activated crosslinking and conjugating agents
US5989842A (en) * 1995-12-29 1999-11-23 Bio-Tez Berlin-Buch Gmbh Method of marking biomolecules using horseradish peroxidase
US6005079A (en) * 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6124435A (en) * 1992-08-05 2000-09-26 Genetech, Inc. Carbohydrate-directed cross-linking reagents
US6218160B1 (en) * 1997-10-31 2001-04-17 Roche Diagnostics Corporation Site-specific conjugation of glycoproteins
US6252053B1 (en) * 1998-09-16 2001-06-26 Nichirei Corporation Enzyme-antibody complex and a method for manufacturing the same
US6537519B2 (en) * 2000-01-11 2003-03-25 Aventis Behring Gmbh Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases
US6576746B2 (en) * 1998-10-13 2003-06-10 Immunomedics, Inc. Site-specific labeling of disulfide-containing targeting vectors
US6613564B2 (en) * 1999-12-22 2003-09-02 Nichirei Corporation Enzyme-protein complex
US6630307B2 (en) * 1999-05-07 2003-10-07 Quantum Dot Corporation Method of detecting an analyte in a sample using semiconductor nanocrystals as a detectable label
US6649138B2 (en) * 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US6670113B2 (en) * 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
US6682596B2 (en) * 2000-12-28 2004-01-27 Quantum Dot Corporation Flow synthesis of quantum dot nanocrystals
US20040115165A1 (en) * 2002-11-25 2004-06-17 Perry Rosen Bifunctional polyethylene glycol derivatives
US6800728B2 (en) * 2000-03-22 2004-10-05 Solulink Biosciences, Inc. Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US6815064B2 (en) * 2001-07-20 2004-11-09 Quantum Dot Corporation Luminescent nanoparticles and methods for their preparation
US20040265922A1 (en) * 2003-06-24 2004-12-30 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences
US20050012182A1 (en) * 2003-07-19 2005-01-20 Samsung Electronics Co., Ltd. Alloy type semiconductor nanocrystals and method for preparing the same
US20050158770A1 (en) * 2003-12-22 2005-07-21 Ventana Medical Systems, Inc. Microwave mediated synthesis of nucleic acid probes
US20050186642A1 (en) * 2004-02-24 2005-08-25 Biocare Medical, Inc. Immunoassay reagents and methods of use thereof
US20060020134A1 (en) * 2004-02-13 2006-01-26 Davis Paul D Selective and specific preparation of discrete peg compounds
US20060100976A1 (en) * 2004-10-26 2006-05-11 Ulead Systems, Inc. Method for searching image files
US20060246523A1 (en) * 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
US20060246524A1 (en) * 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1564604A (en) 1925-06-12 1925-12-08 Chas S Hodges Water wheel
GB782420A (en) * 1954-08-23 1957-09-04 Ici Ltd New hydrazides
IL71947A (en) * 1984-05-29 1987-10-30 Yeda Research And Dev Comp Ltd Enzyme hydrazides and method for detection and determination of glycoconjugates
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
WO1988007200A1 (en) * 1987-03-19 1988-09-22 Perry, Robert, Edward Monoclonal antibody conjugation
US6326136B1 (en) * 1988-04-01 2001-12-04 Digene Corporation Macromolecular conjugate made using unsaturated aldehydes
US5157123A (en) 1989-03-13 1992-10-20 Georgetown University S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent
KR930702683A (ko) 1990-10-22 1993-09-09 챨스 엠. 브록 항체 등에 효소 등을 커플링시키기 위한 동종이작용성 제제
JP3236667B2 (ja) 1991-06-28 2001-12-10 三菱化学株式会社 ヒト型モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ並びに抗腫瘍剤
DE19649390A1 (de) * 1996-11-29 1998-06-04 Boehringer Mannheim Gmbh Antigenspezifischer IgG-Nachweis
KR19990029749A (ko) 1997-09-17 1999-04-26 미우라 아끼라 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
DE19816550A1 (de) * 1997-12-24 1999-06-24 Roche Diagnostics Gmbh Universell verwendbarer Aufbau eines Analysenelements und dessen Einsatz zur Analytbestimmung
EP0990903B1 (en) 1998-09-18 2003-03-12 Massachusetts Institute Of Technology Biological applications of semiconductor nanocrystals
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
EP1170018A4 (en) 1999-03-17 2002-04-17 Mitsubishi Chem Corp COMPLEX LINKED BY A LIGAND
US20050074499A1 (en) 1999-03-17 2005-04-07 Mitsubishi Chemical Corporation Ligand-bonded complex
GB9919338D0 (en) 1999-08-16 1999-10-20 Celltech Therapeutics Ltd Biological products
EP1118335A1 (en) * 2000-01-11 2001-07-25 Aventis Behring GmbH Method for the production of conjugates for the treatment of allergic reactions and autoimmune diseases
NZ532027A (en) * 2001-10-10 2008-09-26 Neose Technologies Inc Remodeling and glycoconjugation of peptides
US20030149246A1 (en) 2002-02-01 2003-08-07 Russell John C. Macromolecular conjugates and processes for preparing the same
CA2499075A1 (en) * 2002-09-16 2004-03-25 Elusys Therapeutics, Inc. Production of bispecific molecules using polyethylene glycol linkers
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
JP4740862B2 (ja) 2003-05-07 2011-08-03 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 合金化された半導体量子ドットおよび合金化された濃度勾配量子ドット、これらの量子ドットを含むシリーズ、ならびにこれらに関する方法
US7642064B2 (en) 2003-06-24 2010-01-05 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
US7361516B2 (en) 2004-09-24 2008-04-22 The United States Of America As Represented By The Secretary Of The Navy Field of modular multifunctional ligands
EP1945262A2 (en) 2005-10-20 2008-07-23 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
ES2804129T3 (es) 2005-11-23 2021-02-03 Ventana Med Syst Inc Conjugado anticuerpo-enzima

Patent Citations (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090B1 (US20070117153A1-20070524-C00013.png) * 1968-09-24 1982-07-20
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3839153A (en) * 1970-12-28 1974-10-01 Akzona Inc Process for the detection and determination of specific binding proteins and their corresponding bindable substances
US4002532A (en) * 1974-10-21 1977-01-11 Weltman Joel K Enzyme conjugates
US4101380A (en) * 1975-06-12 1978-07-18 Research Products Rehovot Ltd. Process for the cross-linking of proteins
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4200436A (en) * 1976-09-30 1980-04-29 Mochida Seiyaku Kabushiki Kaisha Immunochemical measuring process
US4182695A (en) * 1977-02-24 1980-01-08 Boehringer Mannheim Gmbh Polyamide-fixed biologically active protein
US4232119A (en) * 1977-03-04 1980-11-04 Pharmacia Diagnostics Ab Reagent for use in immunochemical assay methods
US4235960A (en) * 1977-07-29 1980-11-25 The Medical College Of Wisconsin, Inc. Competitive enzyme-linked immunoassay
US4218539A (en) * 1978-03-24 1980-08-19 Weltman Joel K Enzyme conjugates and method of preparation and use
US4433059A (en) * 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4454226A (en) * 1982-03-17 1984-06-12 Majid Ali Enzymatic immunoassay
US4657853A (en) * 1984-09-14 1987-04-14 E. I. Du Pont De Nemours And Company Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4994385A (en) * 1987-10-30 1991-02-19 Abbott Laboratories Heterobifunctional coupling agents
US5002883A (en) * 1987-10-30 1991-03-26 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
US5053520A (en) * 1988-09-22 1991-10-01 Abbott Laboratories Heterobifunctional maleimido containing coupling agents
US5063109A (en) * 1988-10-11 1991-11-05 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
US5191066A (en) * 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
US6124435A (en) * 1992-08-05 2000-09-26 Genetech, Inc. Carbohydrate-directed cross-linking reagents
US6005079A (en) * 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5800988A (en) * 1992-08-21 1998-09-01 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5840526A (en) * 1992-08-21 1998-11-24 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5874541A (en) * 1992-08-21 1999-02-23 Vrije Universiteit Immunoglobulins devoid of light chains
US5759808A (en) * 1992-08-21 1998-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6015695A (en) * 1992-08-21 2000-01-18 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5648218A (en) * 1993-02-12 1997-07-15 Sealite Sciences, Inc. Preparation of photoprotein conjugates and methods of use thereof
US6160153A (en) * 1994-12-02 2000-12-12 Abbott Laboratories Phosphatase activated crosslinking conjugating and reducing agents; methods of using such agents; and reagents comprising phosphatase activated crosslinking and conjugating
US5789219A (en) * 1994-12-02 1998-08-04 Abbott Laboratories Phosphatase activated crosslinking conjugating and reducing agents; methods of using such agents; and reagents comprising phosphatase activated crosslinking and conjugating agents
US6057429A (en) * 1994-12-02 2000-05-02 Abbott Laboratories Phosphatase activated crosslinking, conjugating and reducing agents; methods of using such agents; and reagents comprising phosphatase activated crosslinking and conjugating agents
US5989842A (en) * 1995-12-29 1999-11-23 Bio-Tez Berlin-Buch Gmbh Method of marking biomolecules using horseradish peroxidase
US6218160B1 (en) * 1997-10-31 2001-04-17 Roche Diagnostics Corporation Site-specific conjugation of glycoproteins
US6252053B1 (en) * 1998-09-16 2001-06-26 Nichirei Corporation Enzyme-antibody complex and a method for manufacturing the same
US6576746B2 (en) * 1998-10-13 2003-06-10 Immunomedics, Inc. Site-specific labeling of disulfide-containing targeting vectors
US6630307B2 (en) * 1999-05-07 2003-10-07 Quantum Dot Corporation Method of detecting an analyte in a sample using semiconductor nanocrystals as a detectable label
US6613564B2 (en) * 1999-12-22 2003-09-02 Nichirei Corporation Enzyme-protein complex
US20040002146A1 (en) * 1999-12-22 2004-01-01 Nichirei Corporation Enzyme-protein complex
US6537519B2 (en) * 2000-01-11 2003-03-25 Aventis Behring Gmbh Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases
US6800728B2 (en) * 2000-03-22 2004-10-05 Solulink Biosciences, Inc. Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US6649138B2 (en) * 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US6682596B2 (en) * 2000-12-28 2004-01-27 Quantum Dot Corporation Flow synthesis of quantum dot nanocrystals
US6670113B2 (en) * 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
US6815064B2 (en) * 2001-07-20 2004-11-09 Quantum Dot Corporation Luminescent nanoparticles and methods for their preparation
US20040115165A1 (en) * 2002-11-25 2004-06-17 Perry Rosen Bifunctional polyethylene glycol derivatives
US20040265922A1 (en) * 2003-06-24 2004-12-30 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences
US20050012182A1 (en) * 2003-07-19 2005-01-20 Samsung Electronics Co., Ltd. Alloy type semiconductor nanocrystals and method for preparing the same
US20050158770A1 (en) * 2003-12-22 2005-07-21 Ventana Medical Systems, Inc. Microwave mediated synthesis of nucleic acid probes
US20060020134A1 (en) * 2004-02-13 2006-01-26 Davis Paul D Selective and specific preparation of discrete peg compounds
US20050186642A1 (en) * 2004-02-24 2005-08-25 Biocare Medical, Inc. Immunoassay reagents and methods of use thereof
US20060100976A1 (en) * 2004-10-26 2006-05-11 Ulead Systems, Inc. Method for searching image files
US20060246523A1 (en) * 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
US20060246524A1 (en) * 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates
US20090181398A1 (en) * 2005-04-28 2009-07-16 Christina Bauer Nanoparticle conjugates

Cited By (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658389B2 (en) 2005-04-28 2014-02-25 Ventana Medical Systems, Inc. Antibody conjugates
US20060246524A1 (en) * 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates
US11359185B2 (en) 2005-04-28 2022-06-14 Ventana Medical Systems, Inc. Antibody conjugates
US20060246523A1 (en) * 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
US9315789B2 (en) 2005-04-28 2016-04-19 Ventana Medical Systems, Inc. Antibody conjugates
US20090176253A1 (en) * 2005-04-28 2009-07-09 Christopher Bieniarz Antibody conjugates
US9310373B2 (en) 2005-11-23 2016-04-12 Ventana Medical Systems, Inc. Molecular conjugate
US20100136652A1 (en) * 2005-11-23 2010-06-03 Christopher Bieniarz Molecular Conjugate
US8686122B2 (en) 2005-11-23 2014-04-01 Ventana Medical Systems, Inc. Molecular conjugate
US20130295641A1 (en) * 2005-12-12 2013-11-07 Innova Biosciences, Ltd. Production of Conjugates
US9719986B2 (en) 2006-11-01 2017-08-01 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof preparation and method for their preparation and use
US20100184087A1 (en) * 2006-11-01 2010-07-22 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US20100297725A1 (en) * 2006-11-01 2010-11-25 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US20080268462A1 (en) * 2006-11-01 2008-10-30 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US20180120306A1 (en) * 2006-11-01 2018-05-03 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US8618265B2 (en) 2006-11-01 2013-12-31 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US8846320B2 (en) * 2006-11-01 2014-09-30 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US11092594B2 (en) * 2006-11-01 2021-08-17 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US7695929B2 (en) * 2006-11-01 2010-04-13 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US20080274463A1 (en) * 2007-05-04 2008-11-06 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
US7682789B2 (en) * 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
US9575067B2 (en) 2007-05-23 2017-02-21 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US8486620B2 (en) 2007-05-23 2013-07-16 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US8445191B2 (en) 2007-05-23 2013-05-21 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US9017954B2 (en) 2007-05-23 2015-04-28 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US9103822B2 (en) 2007-05-23 2015-08-11 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US10517957B2 (en) 2007-08-17 2019-12-31 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US11717514B2 (en) 2007-08-17 2023-08-08 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US11083710B2 (en) 2007-08-17 2021-08-10 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10046054B2 (en) 2007-08-17 2018-08-14 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10517956B2 (en) 2007-08-17 2019-12-31 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US11298341B2 (en) 2007-08-17 2022-04-12 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10485878B2 (en) 2007-08-17 2019-11-26 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US8907058B2 (en) 2007-08-17 2014-12-09 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10624970B2 (en) 2007-08-17 2020-04-21 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10624971B2 (en) 2007-08-17 2020-04-21 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10406240B2 (en) 2007-08-17 2019-09-10 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US11318121B2 (en) 2007-08-17 2022-05-03 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US11369590B2 (en) 2007-08-17 2022-06-28 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US11504357B2 (en) 2007-08-17 2022-11-22 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10624969B2 (en) 2007-08-17 2020-04-21 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10828282B2 (en) 2007-08-17 2020-11-10 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10646581B2 (en) 2007-08-17 2020-05-12 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US20100324008A1 (en) * 2007-08-17 2010-12-23 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2009055387A1 (en) * 2007-10-22 2009-04-30 Thermo Fisher Scientific Polymerized conjugates for biological applications
US20100203533A1 (en) * 2007-10-22 2010-08-12 Pierce Biotechnology, Inc. Polymerized conjugates for biological applications
US8007998B2 (en) 2007-10-22 2011-08-30 Pierce Biotechnology, Inc. Polymerized conjugates for biological applications
US10718693B2 (en) 2008-06-05 2020-07-21 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
US8703490B2 (en) 2008-06-05 2014-04-22 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
WO2010078376A3 (en) * 2008-12-30 2010-09-16 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
WO2010078376A2 (en) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
WO2011082293A1 (en) 2009-12-31 2011-07-07 Ventana Medical Systems, Inc. Methods for producing uniquely specific nucleic acid probes
US20110203023P1 (en) * 2010-02-16 2011-08-18 Menachem Bronstein Gypsophila Plant Named 'Pearl Blossom''
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US11155800B2 (en) 2010-02-25 2021-10-26 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10557128B2 (en) 2010-02-25 2020-02-11 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2012003476A2 (en) 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Hapten conjugates for target detection
US10883999B2 (en) 2010-07-02 2021-01-05 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry
WO2012003478A2 (en) 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry
US10078083B2 (en) 2010-07-02 2018-09-18 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry
US9291597B2 (en) 2010-07-02 2016-03-22 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry
US9127028B2 (en) 2010-08-16 2015-09-08 Ventana Medical Systems, Inc. Substrates for chromogenic detection and methods of use in detection assays and kits
WO2012116949A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Application of quantum dots for nuclear staining
US9448231B2 (en) 2011-02-28 2016-09-20 Ventana Medical Systems, Inc. Application of quantum dots for nuclear staining
WO2013167387A1 (en) 2012-05-10 2013-11-14 Ventana Medical Systems, Inc. Uniquely specific probes for pten, pik3ca, met, top2a, and mdm2
WO2014009535A2 (en) 2012-07-12 2014-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
WO2014023706A1 (en) 2012-08-06 2014-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for screening patients with a cancer
WO2014048942A1 (en) 2012-09-25 2014-04-03 Ventana Medical Systems, Inc. Probes for pten, pik3ca, met, and top2a, and method for using the probes
US9636413B2 (en) 2012-11-15 2017-05-02 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
US10912840B2 (en) 2012-11-15 2021-02-09 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
US9782493B2 (en) 2012-11-15 2017-10-10 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
WO2015001082A1 (en) 2013-07-05 2015-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
WO2015036405A1 (en) 2013-09-10 2015-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating basal cell carcinoma
US11931430B2 (en) 2013-10-18 2024-03-19 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
US11045564B2 (en) 2013-10-18 2021-06-29 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
US11951190B2 (en) 2013-10-18 2024-04-09 Novartis Ag Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
US10398791B2 (en) 2013-10-18 2019-09-03 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10471160B2 (en) 2013-10-18 2019-11-12 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
US10898596B2 (en) 2015-01-07 2021-01-26 Endocyte, Inc. Conjugates for imaging
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
WO2017202962A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
WO2018011107A1 (en) 2016-07-11 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of er-alpha 46 in methods and kits for assessing the status of breast cancer
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2018046736A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018055080A1 (en) 2016-09-22 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
WO2018055023A1 (en) 2016-09-22 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of lung cancer
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
WO2018146239A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker for outcome in aml patients
WO2018162404A1 (en) 2017-03-06 2018-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker for outcome in aml patients
WO2018172540A1 (en) 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to predict the progression of alzheimer's disease
WO2018189215A1 (en) 2017-04-12 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from hepatocellular carcinoma
WO2019038219A1 (en) 2017-08-21 2019-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) NEW PROGNOSTIC METHOD OF PANCREATIC CANCER
WO2019043138A1 (en) 2017-09-01 2019-03-07 INSERM (Institut National de la Santé et de la Recherche Médicale) METHOD FOR PREDICTING OUTCOME OF CANCER
WO2019092269A1 (en) 2017-11-13 2019-05-16 F. Hoffmann-La Roche Ag Devices for sample analysis using epitachophoresis
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2020074742A1 (en) 2018-10-12 2020-04-16 F. Hoffmann-La Roche Ag Detection methods for epitachophoresis workflow automation
WO2020089428A1 (en) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
WO2020089432A1 (en) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
WO2020141199A1 (en) 2019-01-03 2020-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
EP4059569A1 (en) 2019-01-03 2022-09-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
WO2020148349A1 (en) 2019-01-16 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Variants of erythroferrone and their use
WO2020165370A1 (en) 2019-02-13 2020-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020182932A1 (en) 2019-03-13 2020-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) New gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2020193740A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020216832A1 (en) 2019-04-24 2020-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the response of antipsychotic drugs
WO2020229521A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for inhibiting or reducing bacterial biofilms on a surface
WO2020229437A1 (en) 2019-05-14 2020-11-19 F. Hoffmann-La Roche Ag Devices and methods for sample analysis
WO2020245155A1 (en) 2019-06-03 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating a treatment regimen
WO2021001539A1 (en) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to detect and treat eosinophilic fasciitis
WO2021044012A1 (en) 2019-09-05 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment and pronostic of acute myeloid leukemia
WO2021074391A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing nasal intestinal type adenocarcinomas
WO2021170777A1 (en) 2020-02-28 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
WO2021186014A1 (en) 2020-03-20 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from a cancer
WO2021250106A1 (en) 2020-06-10 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and prognosing cancer like glioblastoma
WO2021255204A1 (en) 2020-06-18 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2022002873A1 (en) 2020-06-30 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
WO2022002874A1 (en) 2020-06-30 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
WO2022018163A1 (en) 2020-07-22 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting survival time in patients suffering from cancer
WO2022064049A1 (en) 2020-09-28 2022-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing brucella infection
WO2022084327A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the response to tnf inhibitors
WO2022096633A1 (en) 2020-11-06 2022-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treating polycystic ovary syndrome (pcos)
WO2022136252A1 (en) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for prognosis the humoral response of a subject prior to vaccination
WO2022135753A1 (en) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for prognosis the humoral response of a subject prior to vaccination
WO2022152698A1 (en) 2021-01-12 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of npdk-d to evaluate cancer prognosis
WO2022171611A1 (en) 2021-02-09 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to pronostic lung cancer
WO2022194949A1 (en) 2021-03-17 2022-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing pancreatic cancer
WO2022207566A1 (en) 2021-03-29 2022-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to evaluate pancreatic cancer prognosis
WO2022223791A1 (en) 2021-04-23 2022-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cell senescence accumulation related disease
WO2023280790A1 (en) 2021-07-05 2023-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2023089159A1 (en) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy targeting stroma/tumor cell crosstalk to treat a cancer
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl)

Also Published As

Publication number Publication date
JP2009521405A (ja) 2009-06-04
HK1121054A1 (en) 2009-04-17
CN101535244A (zh) 2009-09-16
EP3095467B1 (en) 2020-05-06
HK1198485A1 (en) 2015-05-08
CN104090095A (zh) 2014-10-08
AU2006318438A1 (en) 2007-05-31
EP1951316B1 (en) 2015-08-19
US8686122B2 (en) 2014-04-01
US20160195540A1 (en) 2016-07-07
EP2963011A1 (en) 2016-01-06
WO2007062177A3 (en) 2009-05-28
US20100136652A1 (en) 2010-06-03
ES2677555T3 (es) 2018-08-03
EP1951316A2 (en) 2008-08-06
DK2963011T3 (en) 2018-08-06
AU2006318438B2 (en) 2011-09-22
WO2007062177A2 (en) 2007-05-31
ES2804129T3 (es) 2021-02-03
CA2631005C (en) 2017-02-28
ES2548518T3 (es) 2015-10-19
CA2631005A1 (en) 2007-05-31
CN101535244B (zh) 2014-07-23
DK1951316T3 (en) 2015-08-31
EP2963011B1 (en) 2018-05-09
EP3095467A1 (en) 2016-11-23
US20140205995A1 (en) 2014-07-24
JP5199880B2 (ja) 2013-05-15
CN104090095B (zh) 2016-06-01
US9310373B2 (en) 2016-04-12

Similar Documents

Publication Publication Date Title
US9310373B2 (en) Molecular conjugate
JP6770150B2 (ja) 免疫組織化学およびｉｎ ｓｉｔｕハイブリダーゼーションのためのポリマー担体
JP5628476B2 (ja) 抗体コンジュゲート
JPS6121227B2 (US20070117153A1-20070524-C00013.png)
JP2003531213A (ja) 金属キレート化複合物
US4894348A (en) Fluorescein-conjugated proteins with enhanced fluorescence
JPH09508389A (ja) フェニルボロン酸錯体
JPH04268455A (ja) イムノセンソリートランスデューサー
JP4699756B2 (ja) 親水性化学発光アクリジニウムラベル化剤
Husain et al. Fc site-specific labeling of immunoglobulins with calf intestinal alkaline phosphatase
US5852178A (en) Phenylboronic acid complexing reagents for conjugating biologically active molecules
WO2017211799A1 (en) Background blockers for binding assays
KR100819064B1 (ko) 생분자 고정화 링커

Legal Events

Date Code Title Description
AS Assignment

Owner name: VENTANA MEDICAL SYSTEMS, INC., ARIZONA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BIENIARZ, CHRISTOPHER;ASHWORTH-SHARPE, JULIA;KERNAG, CASEY A.;AND OTHERS;REEL/FRAME:020264/0285;SIGNING DATES FROM 20071128 TO 20071214

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION